STTK - NASDAQ
Shattuck Labs, Inc.
$4.89
+0.43%Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
At a Glance
Live SnapshotShattuck Labs, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Shattuck Labs, Inc. Cash Flow Statement
STTK • NASDAQ
| Shattuck Labs, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||
-48.8M | -75.4M | -87.3M | -101.9M | -45M | -36.6M | -24M | -7.4M | |
3.7M | 3.8M | 4M | 3.1M | 1.4M | 618K | 537K | 255K | |
0.0 | 0.0 | 0.0 | 0.0 | 3M | 1K | -166K | -404K | |
7M | 9.5M | 6.9M | 6.5M | 5.5M | 1.3M | 461K | 425K | |
-971K | -1.5M | -816K | 2.4M | 1.5M | 89K | -41K | 2.7M | |
-785K | 3M | -4.1M | -4.5M | -23.5M | 970K | 2.2M | -2.5M | |
-39.9M | -60.5M | -81.2M | -94.5M | -57.1M | -33.7M | -21M | -6.9M | |
INVESTING ACTIVITIES | ||||||||
-71K | -59K | -407K | -11.6M | -7.9M | -727K | -470K | -1.2M | |
(0.0) | (0.0) | (0.0) | (104K) | (2.5M) | (145.6M) | (3.1M) | (0.0) | |
-43.4M | -93.6M | -79.7M | -132.4M | -204.1M | -183.2M | -44.3M | -28.7M | |
35.6M | 85.1M | 191M | 193.3M | 201.6M | 37.6M | 41.1M | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | -2.5M | -145.6M | -3.1M | -15K | |
-7.9M | -8.5M | (110.9M) | (49.4M) | -10.4M | -146.3M | -3.6M | -29.9M | |
FINANCING ACTIVITIES | ||||||||
44.6M | -17K | 48.7M | 171K | 1.9M | 232.3M | 0.0 | 0.0 | |
-65K | 804K | -53K | 0.0 | 0.0 | -19.1M | -64K | -152K | |
44.6M | 787K | 48.6M | 171K | 1.9M | 330.9M | -64K | 35.1M | |
CASH FLOW SUMMARY | ||||||||
-3.2M | -68.2M | 78.2M | -44.9M | -65.6M | 150.9M | -24.6M | -1.7M | |
57.4M | 125.6M | 47.4M | 92.3M | 157.9M | 7M | 31.6M | 33.3M | |
54.2M | 57.4M | 125.6M | 47.4M | 92.3M | 157.9M | 7M | 31.6M | |
-40M | -60.6M | -81.6M | -106.1M | -65M | -34.4M | -21.4M | -8.1M |
SEC Filings
STTK - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 02, 2026 | May 28, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 08, 2026 | May 28, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 05, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 05, 2026 | March 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 05, 2026 | February 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 22, 2026 | January 22, 2026 | 2026 | |
S-3 S-3 N/A | January 13, 2026 | January 13, 2026 | ||
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your STTK research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.